Use of an interleukin 1 receptor antagonist and/or...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01) A61K 31/40 (2006.01) A61K 38/20 (2006.01) A61P 3/10 (2006.01)

Patent

CA 2487362

Substances that inhibit the action of the members of the IL-1 /NF- B pathway can be used for protecting and preserving -cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.

Selon cette invention, des substances inhibant l'action des éléments de la voie IL-1.beta./NF-.kappa.B peuvent être utilisées pour protéger et préserver la masse et la fonction de cellules .beta. chez des patients prédiabétiques et diabétiques de type 2. De manière spécifique, cette invention porte sur l'utilisation d'un antagoniste du récepteur de l'interleukine 1 (IL-1Ra) et/ou de pyrrolidinedithiocarbamate (PDTC) pour le traitement ou la prophylaxie du diabète de type 2, ainsi que sur une méthode de traitement du diabète de type 2.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of an interleukin 1 receptor antagonist and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of an interleukin 1 receptor antagonist and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an interleukin 1 receptor antagonist and/or... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1502659

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.